Skip to main content

Table 2 Multivariable linear regression analysis to evaluate the therapeutic effect of mirabegron on the fourth-year HAM-BDSS

From: Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in Japan

Variable

Model 1

Model 2

Model 3

β

95%CI

p value

β

95%CI

p value

β

95%CI

p value

Total score

         

Mirabegron started in 4th year

− 5.86

− 9.15, − 2.57

0.001

− 5.79

− 9.10, − 2.49

0.001

− 5.82

− 9.13, − 2.50

0.001

HAM-BDSS (3rd year)

0.88

0.80, 0.96

< 0.001

0.87

0.79, 0.95

< 0.001

0.86

0.78, 0.95

< 0.001

Age (1-year increase)

–

–

–

− 0.02

− 0.09, 0.05

0.592

− 0.02

− 0.08, 0.05

0.673

Sex (female vs. male)

–

–

–

− 0.93

− 2.61, 0.77

0.281

− 0.79

− 2.54, 0.96

0.373

α1 adrenergic-receptor antagonists

–

–

–

–

–

–

1.80

− 0.45, 4.03

0.115

Cholinergic agonists

–

–

–

–

–

–

− 1.75

− 5.44, 1.94

0.350

Anticholinergics

–

–

–

–

–

–

0.37

− 1.97, 2.71

0.752

Storage symptom score

         

Mirabegron started in 4th year

− 2.73

− 5.06, − 0.41

0.022

− 2.64

− 4.97, − 0.32

0.026

− 2.72

− 5.02, − 0.42

0.021

HAM-BDSS (3rd year)

0.81

0.69, 0.92

< 0.001

0.79

0.67, 0.90

< 0.001

0.79

0.68, 0.91

< 0.001

Age (1-year increase)

–

–

–

–0.002

− 0.05, 0.05

0.926

0.00

− 0.05, 0.05

0.994

Sex (female vs. male)

–

–

–

− 0.94

− 2.11, 0.23

0.115

− 1.04

− 2.24, 0.16

0.088

α1 adrenergic-receptor antagonists

–

–

–

–

–

–

0.85

− 0.68, 2.38

0.275

Cholinergic agonists

–

–

–

–

–

–

− 1.45

− 4.00, 1.09

0.261

Anticholinergics

–

–

–

–

–

–

1.44

− 0.17, 3.05

0.079

Voiding symptom score

         

Mirabegron started in 4th year

− 2.83

− 4.81, − 0.87

0.005

− 2.83

− 4.82, − 0.84

0.006

− 2.81

− 4.80, − 0.82

0.006

HAM-BDSS (3rd year)

0.92

0.85, 0.99

< 0.001

0.92

0.84, 0.99

< 0.001

0.91

0.83, 0.99

< 0.001

Age (1-year increase)

–

–

–

− 0.01

− 0.05, 0.03

0.626

− 0.01

− 0.05, 0.03

0.662

Sex (female vs male)

–

–

–

− 0.02

− 1.04, 0.99

0.963

0.22

− 0.83, 1.26

0.679

α1 adrenergic-receptor antagonists

–

–

–

–

–

− 

0.82

− 0.53, 2.17

0.232

Cholinergic agonists

–

–

–

–

–

–

− 0.15

− 2.37, 2.07

0.893

Anticholinergics

–

–

–

–

–

–

− 1.06

− 2.46, 0.35

0.139

  1. Multivariable linear regression analysis adjusted by the third-year HAM-BDSS: model 1 included the third-year HAM-BDSS and initiation of mirabegron in the fourth year; model 2 was model 1 plus adjustments for age and sex; model 3 was model 2 plus an adjustment for other medications for urinary symptoms
  2. HAM-BDSS, HAM/TSP-bladder dysfunction symptom score